Nora A. A. Alhamshry’s research while affiliated with University of Sadat City and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (6)


Role of lncRNAs in GC Progression. HNF1A-AS1 is elevated in GC and promotes cell cycle progression. It interacts with EGR1, which increases the levels of CDK2, CDK4, and cyclin E1 while inhibiting p21 release. The upregulation of LINC00673 in GC affects CADM4, KLF2, and LATS2, causing GC. GC increases NKX2-1-AS1, NEAT1, and FEZF1-AS1, which inhibit apoptosis and are associated with angiogenesis. The regulation of LINC01314 and KLK4 plays a significant role in the modulation of the VEGF-C/VEGFR-3 axis in GC, influencing tumor proliferation and angiogenesis through the Wnt/β-catenin pathway
LncRNAs involved in GC resistance to chemotherapy. High levels of EIF3J-DT in drug-resistant GC cells activate autophagy by stabilizing ATG14 and inhibiting miR-188-3p, providing a major mechanism for oxaliplatin resistance. MALAT1, SNHG5, and PCAT-1 are essential for GC cisplatin resistance. Cisplatin-resistant GC overexpresses SNHG5, which inhibits apoptosis and modulates resistance genes, decreasing drug sensitivity. By epigenetically regulating the PTEN gene, PCAT-1 is overexpressed in resistant GC cell lines and tumor tissues, contributing to chemotherapy resistance. lncRNA UCA1 is involved in both cisplatin resistance and adriamycin sensitivity in GC by reducing cell apoptosis by negatively regulating miR-27b. The PI3K/Akt/mTOR/p70S6K pathway is often abnormally activated in GC, promoting oncogenesis and chemoresistance. Upregulation of lncRNA HIT000218960 may further contribute to 5-fluorouracil resistance by modulating this pathway
Clinical importance of lncRNAs in GC. Reductions in lncRNAs such as DRAIR, MIAT, and PTCSC3 have shown promise as biomarkers for differentiating gastric cancer (GC) patients in stages I and II from healthy controls. Additionally, MALAT1 levels effectively distinguish between GC patients with and without distant metastasis, while SPRY4-IT1 and H19 are potential candidates for differentiating tumor tissues from non-tumorous tissues. Furthermore, lncRNA AC138128.1 may serve as a predictive biomarker for GC, highlighting the significant role of lncRNAs in improving early detection and treatment strategies for this cancer type
LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance
  • Literature Review
  • Publisher preview available

September 2024

·

88 Reads

·

6 Citations

Functional & Integrative Genomics

·

Rewan Moussa

·

·

[...]

·

Gastric cancer (GC) remains a major public health challenge worldwide. Long non-coding RNAs (lncRNAs) play important roles in the development, progression, and resistance to the treatment of GC, as shown by recent developments in molecular characterization. Still, an in-depth investigation of the lncRNA landscape in GC is absent. However, The objective of this systematic review is to evaluate our present understanding of the role that lncRNA dysregulation plays in the etiology of GC and treatment resistance, with a focus on the underlying mechanisms and clinical implications. Research that described the functions of lncRNA in angiogenesis, stemness, epigenetics, metastasis, apoptosis, development, and resistance to key treatments was given priority. In GC, it has been discovered that a large number of lncRNAs, including MALAT1, HOTAIR, H19, and ANRIL, are aberrantly expressed and are connected with disease-related outcomes. Through various methods such as chromatin remodeling, signal transduction pathways, and microRNA sponging, they modulate hallmark cancer capabilities. Through the activation of stemness programs, epithelial-mesenchymal transition (EMT), and survival signaling, LncRNAs also control resistance to immunotherapy, chemotherapy, and targeted therapies. By clarifying their molecular roles further, we may be able to identify new treatment targets and ways to overcome resistance. This article aims to explore the interplay between lncRNAs, and GC. Specifically, the focus is on understanding how lncRNAs contribute to the etiology of GC and influence treatment resistance in patients with this disease.

View access options

Exploring the interplay of natural products and long non-coding RNAs in colorectal cancer: pathogenesis, diagnosis, and overcoming drug resistance

September 2024

·

109 Reads

·

3 Citations

Naunyn-Schmiedeberg's Archives of Pharmacology

Colorectal cancer (CRC) is recognized as one of the most prevalent malignancies, both in terms of incidence and mortality rates. Current research into CRC has shed light on the molecular mechanisms driving its development. Several factors, including lifestyle, environmental influences, genetics, and diet, play significant roles in its pathogenesis. Natural compounds such as curcumin, tanshinone, lycorine, sinomenine, kaempferol, verbascoside, quercetin, berberine, and fisetin have shown great promise in the prevention and treatment of CRC. Research has also highlighted the significance of non-coding RNAs (ncRNAs) as biomarkers and therapeutic targets in CRC. Among these, long non-coding RNAs (lncRNAs) have been found to regulate the transcription of genes involved in cancer. LncRNAs contribute to cancer stem cell (CSC) proliferation, angiogenesis, epithelial-mesenchymal transition (EMT), and chemoresistance. Specific lncRNAs, including GAS5, LNC00337, HOTAIR, TPT1-AS1, cCSC1, BCAR4, TUG1, and Solh2, play crucial roles in these processes. They hold potential as novel biomarkers, detectable in bodily fluids and tissues, and could serve as therapeutic targets due to their involvement in drug resistance and sensitivity. These insights could improve CRC treatment strategies, addressing resistance to chemotherapy and radiotherapy. This review article aims to provide a comprehensive analysis of the current knowledge regarding the effectiveness of natural anti-cancer agents in CRC treatment. Additionally, it offers an in-depth evaluation of lncRNAs in CRC, their role in the disease’s progression, and their potential applications in its management. Graphical Abstract


LncRNA interference with PTEN/AKT/PI3K route, Wnt/ß-Catenin pathway and mutation of KRAS route
Interference of lncRNAs with TGF-β, EGFR, and PI3K/AKT/mTOR pathways. Several lnc-RNAs (Linc00152, EGFR-AS1, Inc00665) contribute to the sustained activation of those Signaling Pathway
Interference of lncRNAs with JAK2/STAT pathway. SNHG1 contributes to the sustained activation of SOGS 2 which inhibit JAK2/STAT signaling pathway
LncRNAs targeting pathways; MAPK/ERK, EGFR, TGF-β axis, PTEN/AKT/PI3K, PI3K/AKT/mTOR, Wnt/β-catenin, HH, KRAS routs, NF-kB, HH, p53, and HIF-1α in GC
Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay

August 2024

·

99 Reads

·

5 Citations

Medical Oncology

Gastric cancers (GCs) are among the most common and fatal malignancies in the world. Despite our increasing understanding of the molecular mechanisms underlying GC, further biomarkers are still needed for more in-depth examination, focused prognosis, and treatment. GC is one among the long non-coding RNAs, or lncRNAs, that have emerged as key regulators of the pathophysiology of cancer. This comprehensive review focuses on the diverse functions of long noncoding RNAs (lncRNAs) in the development of GC and their interactions with important intracellular signaling pathways. LncRNAs affect GC-related carcinogenic signaling cascades including pathways for EGFR, PI3K/AKT/mTOR, p53, Wnt/β-catenin, JAK/STAT, Hedgehog, NF-κB, and hypoxia-inducible factor. Dysregulated long non-coding RNA (lncRNA) expression has been associated with multiple characteristics of cancer, such as extended growth, apoptosis resistance, enhanced invasion and metastasis, angiogenesis, and therapy resistance. For instance, lncRNAs such as HOTAIR, MALAT1, and H19 promote the development of GC via altering these pathways. Beyond their main roles, GC lncRNAs exhibit potential as diagnostic and prognostic biomarkers. The overview discusses CRISPR/Cas9 genome-modifying methods, antisense oligonucleotides, small molecules, and RNA interference as potential therapeutic approaches to regulate the expression of long noncoding RNAs (lncRNAs). An in-depth discussion of the intricate functions that lncRNAs play in the development of the majority of stomach malignancies is provided in this review. It provides the groundwork for future translational research in lncRNA-based whole processes toward GC by highlighting their carcinogenic effects, regulatory roles in significant signaling cascades, and practical scientific uses as biomarkers and therapeutic targets.


Natural products and long noncoding RNA signatures in gallbladder cancer: a review focuses on pathogenesis, diagnosis, and drug resistance

July 2024

·

203 Reads

·

8 Citations

Naunyn-Schmiedeberg's Archives of Pharmacology

Gallbladder cancer (GBC) is an aggressive and lethal malignancy with a poor prognosis. Long noncoding RNAs (lncRNAs) and natural products have emerged as key orchestrators of cancer pathogenesis through widespread dysregulation across GBC transcriptomes. Functional studies have revealed that lncRNAs interact with oncoproteins and tumor suppressors to control proliferation, invasion, metastasis, angiogenesis, stemness, and drug resistance. Curcumin, baicalein, oleanolic acid, shikonin, oxymatrine, arctigenin, liensinine, fangchinoline, and dioscin are a few examples of natural compounds that have demonstrated promising anticancer activities against GBC through the regulation of important signaling pathways. The lncRNAs, i.e., SNHG6, Linc00261, GALM, OIP5-AS1, FOXD2-AS1, MINCR, DGCR5, MEG3, GATA6-AS, TUG1, and DILC, are key players in regulating the aforementioned processes. For example, the lncRNAs FOXD2-AS1, DILC, and HOTAIR activate oncogenes such as DNMT1, Wnt/β-catenin, BMI1, and c-Myc, whereas MEG3 and GATA6-AS suppress the tumor proteins NF-κB, EZH2, and miR-421. Clinically, specific lncRNAs can serve as diagnostic or prognostic biomarkers based on overexpression correlating with advanced TNM stage, metastasis, chemoresistance, and poor survival. Therapeutically, targeting aberrant lncRNAs with siRNA or antisense oligos disrupts their oncogenic signaling and inhibits GBC progression. Overall, dysfunctional lncRNA regulatory circuits offer multiple avenues for precision medicine approaches to improve early GBC detection and overcome this deadly cancer. They have the potential to serve as novel biomarkers as they are detectable in bodily fluids and tissues. These findings enhance gallbladder treatments, mitigating resistance to chemo- and radiotherapy.



The potential relevance of long non-coding RNAs in colorectal cancer pathogenesis and treatment: A review focus on signaling pathways

December 2023

·

78 Reads

·

10 Citations

Pathology - Research and Practice

Colorectal cancer (CRC) is one of the most frequent cancers in incidence and mortality. Despite advances in cancer biology, molecular genetics, and targeted treatments, CRC prognosis and survival have not kept pace. This is usually due to advanced staging and metastases at diagnosis. Thus, great importance has been placed upon understanding the molecular pathophysiology behind the development of CRC, which has highlighted the significance of non-coding RNA’s role and associated intracellular signaling pathways in the pathogenesis of the disease. According to recent studies, long non-coding RNAs (lncRNA), a subtype of ncRNAs whose length exceeds 200 nucleotides, have been found to have regulatory functions on multiple levels. Their actions at the transcription, post-transcriptional, translational levels, and epigenetic regulation have made them prime modulators of gene expression. Due to their role in cellular cancer hallmarks, their dysregulation has been linked to several illnesses, including cancer. Furthermore, their clinical relevance has expanded due to their possible detection in blood which has cemented them as potential future biomarkers and thus, potential targets for new therapy. This review will highlight the importance of lncRNAs and related signaling pathways in the development of CRC and their subsequent clinical applications.

Citations (6)


... The EMT mechanistic involves the conversion of normal epithelial cells to mesenchymal cells which proliferate easily (Nakazawa et al. 2017). During this process, the epithelial cell markers are suppressed, along with the enhancement of mesenchymal markers, leading to the encouragement of invasion and proliferation (Odero-Marah et al. 2018;Elimam et al. 2024b). Various lncRNAs could modulate EMT by targeting EMT-linked transcriptional factors (Heery et al. 2017). ...

Reference:

Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance
LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance

Functional & Integrative Genomics

... For example, resveratrol, one of the critical polyphenols contained in red wine, inhibits HCC growth by inhibiting the HGF-c-Met path [226]. Quercetin, a flavonol, has anti-tumor properties and reduces the growth of several tumor cells [227], particularly liver cancer. It inhibits HGFand TGF-α-induced HCC progression by blocking the AKT signaling path [228]. ...

Exploring the interplay of natural products and long non-coding RNAs in colorectal cancer: pathogenesis, diagnosis, and overcoming drug resistance

Naunyn-Schmiedeberg's Archives of Pharmacology

... Similarly, lncRNA also plays an important role in the development of GC. LncRNA affects GC-related carcinogenic signaling cascades including pathways for PI3K/AKT/mTOR, p53, Wnt/b-catenin, JAK/STAT, and others (13). Moreover, Li et al. report that H19 may regulate the immune cell infiltration in carcinogenesis of GC through miR-378a-5p/SERPINH1 signaling, such as B cells, CD4+ T cells (14). ...

Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay

Medical Oncology

... The mechanism of exerting its action is carried out primarily by antioxidation, working with the principle of free radicals' action being responsible for tissue oxidation that leads to the development of tumors. This reducing property of curcumin is facilitated by the methoxy group, 1,3 β-diketone moiety, and phenolic hydroxyl group [79,80]. Studies show that Curcumin inhibits nuclear factor-kB (NF-kB), initially responsible for activating inflammatory cytokines and chemokines, leading to several inflammatory conditions [81]. ...

Natural products and long noncoding RNA signatures in gallbladder cancer: a review focuses on pathogenesis, diagnosis, and drug resistance

Naunyn-Schmiedeberg's Archives of Pharmacology

... Conversely, the lncRNAs that affect the expression of genes at both transcriptional and post-transcriptional levels can be found in the cytoplasm. These cytoplasmic lncRNAs can interact with miRNAs by functioning as competitive endogenous RNAs (ceRNAs), which can impact cytoplasmic proteins and modify RNA metabolism ( Fig. 1) (Mirzaei et al. 2022a, Doghish et al. 2024. ...

Decoding the role of long non-coding RNAs in gallbladder cancer pathogenesis: A review focus on signaling pathways interplay
  • Citing Article
  • February 2024

International Journal of Biological Macromolecules

... Numerous studies have revealed that ncRNAs participate in various cellular processes, such as cell growth, apoptosis, differentiation, and gene expression. ncRNAs can modulate gene expression at different levels, such as transcription, splicing, translation, and epigenetics [32,59]. For instance, lncRNAs can act as a mediator for the LSD1 complex, which is responsible for histone methylation and demethylation, respectively. ...

The potential relevance of long non-coding RNAs in colorectal cancer pathogenesis and treatment: A review focus on signaling pathways
  • Citing Article
  • December 2023

Pathology - Research and Practice